Literature DB >> 23492875

High apolipoprotein E4 allele frequency in FXTAS patients.

Francisca Silva1, Laia Rodriguez-Revenga, Irene Madrigal, Maria Isabel Alvarez-Mora, Rafael Oliva, Montserrat Milà.   

Abstract

PURPOSE: Fragile X-associated tremor/ataxia syndrome is a late-onset neurodegenerative disorder that occurs in FMR1 premutation carriers. It is well known that the apolipoprotein E ε4 allele is a risk factor for neurodegenerative disease. The main goal of this work was to evaluate the apolipoprotein E genotypes and allelic distribution among patients with fragile X-associated tremor/ataxia syndrome.
METHODS: A total of 44 unrelated FMR1 premutation carriers (22 presenting with fragile X-associated tremor/ataxia syndrome and 22 without fragile X-associated tremor/ataxia syndrome) were genotyped.
RESULTS: All the apolipoprotein E ε4/4 genotype carriers detected (100%), and six of the seven apolipoprotein E ε4/3 genotype carriers (85.7%) are patients presenting with fragile X-associated tremor/ataxia syndrome symptoms, whereas only 40% of the apolipoprotein E ε3/3 genotype carriers belong to the fragile X-associated tremor/ataxia syndrome group. The results showed that the presence of the apolipoprotein E ε4 allele increases the risk of developing fragile X-associated tremor/ataxia syndrome (odds ratio = 12.041; P = 0.034).
CONCLUSION: On the basis of these results, we conclude that the presence of at least one apolipoprotein E ε4 allele might act as a genetic factor predisposing individuals to develop fragile X-associated tremor/ataxia syndrome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23492875     DOI: 10.1038/gim.2013.12

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  9 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

2.  Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Andreea L Seritan; Kyoungmi Kim; Ian Benjamin; Ioana Seritan; Randi J Hagerman
Journal:  J Geriatr Psychiatry Neurol       Date:  2016-09-21       Impact factor: 2.680

Review 3.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

4.  Towards an Understanding of Neuropsychiatric Manifestations in Fragile X Premutation Carriers.

Authors:  Aaron D Besterman; Scott A Wilke; Tua-Elisabeth Mulligan; Stephen C Allison; Randi Hagerman; Andreea L Seritan; James A Bourgeois
Journal:  Future Neurol       Date:  2014-03

5.  Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers.

Authors:  Jonathan Polussa; Andrea Schneider; Randi Hagerman
Journal:  Brain Disord Ther       Date:  2014

Review 6.  Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.

Authors:  Fatemeh Nouri Emamzadeh
Journal:  J Mol Neurosci       Date:  2017-07-10       Impact factor: 3.444

7.  Case Report: Coexistence of Alzheimer-Type Neuropathology in Fragile X-Associated Tremor Ataxia Syndrome.

Authors:  Maria Jimena Salcedo-Arellano; Desiree Sanchez; Jun Yi Wang; Yingratana A McLennan; Courtney Jessica Clark; Pablo Juarez; Andrea Schneider; Flora Tassone; Randi J Hagerman; Verónica Martínez-Cerdeño
Journal:  Front Neurosci       Date:  2021-09-17       Impact factor: 4.677

8.  Family history of FXTAS is associated with age-related cognitive-linguistic decline among mothers with the FMR1 premutation.

Authors:  Jessica Klusek; Amanda Fairchild; Carly Moser; Marsha R Mailick; Angela John Thurman; Leonard Abbeduto
Journal:  J Neurodev Disord       Date:  2022-01-14       Impact factor: 4.074

9.  Characterization of the Cerebrospinal Fluid Proteome in Patients with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Diana A Abbasi; Thu T A Nguyen; Deborah A Hall; Erin Robertson-Dick; Elizabeth Berry-Kravis; Stephanie M Cologna
Journal:  Cerebellum       Date:  2021-05-27       Impact factor: 3.847

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.